Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
X4P-001 + Nivolumab in Advanced ccRCC
NCT02923531Phase 2Terminated
- Sponsor
- X4 Pharmaceuticals, Inc.
- Start
- Dec 2016
- Primary completion
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mavorixafor in clear cell renal cell carcinoma (ccRCC), sponsored by X4 Pharmaceuticals, Inc. Primary endpoint: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) up to 16 months. Started Dec 2016; status: terminated.
02
Drugs
mavorixafor
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02923531.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02923531.